{'fraction_non_alphanumeric': 0.031007751937984496, 'fraction_numerical': 0.016795865633074936, 'mean_word_length': 5.458333333333333, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Alfentanil in inpatient palliative medicine: practice survey

INTRODUCTION Alfentanil has less than 0.5% renal excretion 2 and is the opioid of choice in endstage kidney disease (ESKD). Alfentanil was reported in palliative care practice in 1995, four patients were noted to have a reduction in agitation when alfentanil was administered via continuous subcutaneous infusion (CSCI), suggested explanation was the lack of accumulation of active metabolites. A conversion ratio of 10:1 (diamorphine subcutaneously (SC) to alfentanil SC) was proposed in discussion with anaesthetic colleagues. This has been adopted in practice despite a paucity of evidence. We surveyed our practice; whether the 10:1 ratio was being used, and reviewed subsequent dose (SD) titration of CSCIs.